<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02240524</url>
  </required_header>
  <id_info>
    <org_study_id>2014514</org_study_id>
    <nct_id>NCT02240524</nct_id>
  </id_info>
  <brief_title>Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer</brief_title>
  <acronym>HIPEC</acronym>
  <official_title>A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2 Lymphadenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the efficacy of hyperthermic intraperitoneal
      chemotherapy in the treatment of patients with locally advanced gastric cancer after radical
      gastrectomy with D2 lymphadenectomy. It is a multicentric and randomised phase III trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>From the date of surgery to the date of death or to the end of follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>From the date of surgery to the date of recurrence or to the end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>From the date of surgery to the date of locoregional recurrence or to the end of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic metastases-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>From the date of surgery to the date of recurrence or to the end of follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">582</enrollment>
  <condition>Advanced Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>D2 lymphadenectomy and HIPEC and Systemic chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative and postoperative hyperthermic intraperitoneal chemotherapy (twice HIPEC) were performed after radical gastrectomy with D2 lymphadenectomy, followed by 8 cycles of systemic chemotherapy.
HIPEC was conducted within 48 h after surgery: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m^2, 43°C, 60min.
Systemic chemotherapy (XELOX):
Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D2 lymphadenectomy+Systemic chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 cycles of systemic chemotherapy were performed after radical gastrectomy with D2 lymphadenectomy.
Systemic chemotherapy (XELOX):
Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D2 lymphadenectomy</intervention_name>
    <description>The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.</description>
    <arm_group_label>D2 lymphadenectomy and HIPEC and Systemic chemotherapy</arm_group_label>
    <arm_group_label>D2 lymphadenectomy+Systemic chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Systemic chemotherapy</intervention_name>
    <arm_group_label>D2 lymphadenectomy and HIPEC and Systemic chemotherapy</arm_group_label>
    <arm_group_label>D2 lymphadenectomy+Systemic chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HIPEC</intervention_name>
    <arm_group_label>D2 lymphadenectomy and HIPEC and Systemic chemotherapy</arm_group_label>
    <other_name>hyperthermic intraperitoneal chemoperfusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 &lt; age ≤ 65 years old

          -  Male or Non pregnant female

          -  The Eastern Cooperative Oncology Group (ECOG) status ≤ 2

          -  Histologically diagnosed as T4 gastric adenocarcinoma (determined from data obtained
             by endoscopic ultrasound or CT scan)

          -  Have not received cytotoxic chemotherapy, radiotherapy or immunotherapy

          -  White blood cells &gt; 4,000/mm3

          -  neutrophils ≥ 1,500/mm3

          -  platelets ≥ 100,000/mm3

          -  hemoglobin&gt;9g/l

          -  Alanine transaminase (ALT) and aspartate aminotransferase (AST) &lt; or = 2.5 times upper
             limit of nominal (ULN)

          -  total bilirubin (TBIL) &lt; 1.5 times ULN

          -  serum creatinine &lt; 1 times ULN

          -  Having given written informed consent prior to any procedure related to the study

        Exclusion Criteria:

          -  Existence of macroscopic peritoneal implants

          -  Prior malignant tumors with detectable signs of recurrence or distant metastasis

          -  Poorly controlled disease e.g. atrial fibrillation, stenocardia, cardiac
             insufficiency, persistent hypertension despite medicinal treatment, ejection
             fraction&lt;50%

          -  Receiving other cytotoxic chemotherapy

          -  High grade of intra-abdominal adhesions

          -  Contraindication to any therapy contained in this regimen specific to the study
             Without given written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shuzhong cui, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhiyuan fang, Ph.D</last_name>
    <phone>86020666736662012</phone>
    <email>fangjnu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhiyuan fang, Ph.D</last_name>
      <phone>86020666736662012</phone>
      <email>fangjnu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>shuzhong cui, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2014</study_first_submitted>
  <study_first_submitted_qc>September 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2014</study_first_posted>
  <last_update_submitted>September 12, 2014</last_update_submitted>
  <last_update_submitted_qc>September 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric adenocarcinoma</keyword>
  <keyword>HIPEC</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

